Dong-A ST Co., Ltd.
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for Acylated oxyntomodulin peptide analog (US 11,713,344) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due Mar 3, 2027The maintenance fee for Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy (US 10,398,747) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Substituted piperidines having GPR119 agonistic activity (US 10,428,055) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Anti-DR5 antibody and use thereof (US 11,840,574) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,718,174 | Anti-HGF/SF humanized antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 8,420,676 | Novel Oxazolidinone Derivatives In force · High confidence | In force | High confidence | |
| US 7,816,379 | Novel Oxazolidinone Derivatives In force · High confidence | In force | High confidence | |
| US 10,398,747 | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy In force · From the USPTO record | In force | From the USPTO record | |
| US 10,709,752 | Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,813,973 | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy In force · From the USPTO record | In force | From the USPTO record | |
| US 10,159,667 | Composition Containing a Dpp-IV Inhibitor for Preventing or Treating Renal Diseases In force · High confidence | In force | High confidence | |
| US 9,828,339 | Biphenyl derivatives and methods for preparing same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,676,796 | Tricyclic benzoxaborole compound, preparation method and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,809,583 | Oxazolidine-based compound and selective androgen receptor agonist comprising same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 22: 6 patents in force now held by others · 4 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 15 no status recorded